Lesion morphology in age-related macular degeneration and its therapeutic significance

Archives of Ophthalmology

Volumn 124, Issue 6, 2006, Pages 807-812

  Beaumont, Paul E ^a   Kang, H Kwon ^a,b  

^a Eye and Vision Research Institute   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; EYE INJURY; HUMAN; KRUSKAL WALLIS TEST; LASER COAGULATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION;

AGED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES;

EID: 33745022804     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.6.807     Document Type: Review

References (21)

1. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994;112:480-488.
2. Macular Photocoagulation Study Group. Occult choroidal neovascularization: influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol. 1996;114:400-412.
3. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999;117:1329-1345.
4. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol. 2001;131:541-560.
5. Bressler NM; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol. 2001;119:198-207.
6. Blinder KJ, Bradley S, Bressler NM, et al; Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No. 1. Am J Ophthalmol. 2003;136:407-418.
7. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol. 1991;109:1242-1257.
8. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98:1128-1134.
9. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol. 1986;104:694-701.
10. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1990;108:816-824.
11. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.
12. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Principal Investigators; Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22:6-18.
13. Barbazetto I, Burdan A, Bressler NM, et al; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
14. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993;115:786-791.
15. Moisseiev J, Alhalel A, Masuri R, Treister G. The impact of the Macular Photocoagulation Study results on the treatment of exudative age-related macular degeneration. Arch Ophthalmol. 1995;113:185-189.
16. Gelfand YA, Linn S, Miller B. The application of the Macular Photocoagulation Study eligibility criteria for laser treatment in age-related macular degeneration. Ophthalmic Surg Lasers. 1997;28:823-827.
17. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina. 2000;20:325-330.
18. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol. 2002;86:663-669.
19. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1232-1241.
20. Stevens TS, Bressler NM, Maguire MG, et al. Occult choroidal neovascularization in age-related macular degeneration: a natural history study. Arch Ophthalmol. 1997;115:345-350.
21. Bressler SB, Pieramici DJ, Koester JM, Bressler NM. Natural history of minimally classic subfoveal choroidal neovascular lesions in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation: outcomes potentially relevant to management - TAP report No. 6. Arch Ophthalmol. 2004;122:325-329.